Medical Supplies

Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

Retrieved on: 
Monday, April 25, 2022
Pharmaceutical, Consumer, Infectious Diseases, Hospitals, Teens, Children, Clinical Trials, Baby, Maternity, Biotechnology, Medical Supplies, FDA, Health

For hospitalized pediatric patients who do not require invasive mechanical ventilation and/or ECMO, a 5-day treatment course is recommended.

Key Points: 
  • For hospitalized pediatric patients who do not require invasive mechanical ventilation and/or ECMO, a 5-day treatment course is recommended.
  • Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury.
  • Of the 53 pediatric patients enrolled in the CARAVAN study, no new safety signals were apparent for patients treated with Veklury.
  • Veklury was approved by the FDA in October 2020, for adults and pediatric patients 12 years of age and older and weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization.

PHASE Scientific Americas Launches Online Shop for At-Home COVID-19 Tests

Retrieved on: 
Monday, April 25, 2022
Other Health, Online Retail, Pharmaceutical, Oncology, Consumer, Infectious Diseases, Retail, Other Consumer, Biotechnology, Seniors, Medical Supplies, Health, Society, Adoption, Shopify, NIH, COVID-19, Ageing, Diagnosis, Shop, Hospital, Severe acute respiratory syndrome coronavirus 2, National, Infection, NPA, Commerce, PPA, EUA, Microbiology Spectrum, Omicron, School, View, UCLA, Health, Cancer, Pharmaceutical industry, Vaccine

PHASE Scientific Americas (PHASE Scientific), a high-growth biotech company founded by bioengineers from UCLA, announces that its EUA approved INDICAID COVID-19 Rapid Antigen At-Home Test (INDICAID OTC) is now available for non-prescription home use in the United States through its new Shop INDICAID online store, shop.indicaidusa.com .

Key Points: 
  • PHASE Scientific Americas (PHASE Scientific), a high-growth biotech company founded by bioengineers from UCLA, announces that its EUA approved INDICAID COVID-19 Rapid Antigen At-Home Test (INDICAID OTC) is now available for non-prescription home use in the United States through its new Shop INDICAID online store, shop.indicaidusa.com .
  • The performance of INDICAID for professional use was published in a peer-reviewed article in the American Society for Microbiologys journal, Microbiology Spectrum .
  • About the INDICAID COVID-19 Rapid Antigen At-Home Test:
    The INDICAID COVID-19 Rapid Antigen At-Home Test is authorized for nonprescription home use.
  • For additional information about PHASEs over-the-counter home-use offerings, see https://us.phasescientific.com/indicaid-otc-rapid-antigen-test/
    About PHASE Scientific International LTD:
    PHASE Scientific Americas is part of PHASE Scientific International LTD, a high-growth biotech company with a mission to inspire a new state of health.

Global In Vitro Diagnostics (IVD) Analyzers Market to 2026 - Featuring Abbott Laboratories, Danaher and Sysmex Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 25, 2022
Infectious Diseases, Other Health, Health, Pharmaceutical, Medical Supplies, IVD, Technology, Non-functional testing, Industry, Automation, Medical device, Risk management

Estimation of the market size and analyses of global market trends, with data from 2019 to 2021 and projections of compound annual growth rates (CAGRs) through 2026

Key Points: 
  • Estimation of the market size and analyses of global market trends, with data from 2019 to 2021 and projections of compound annual growth rates (CAGRs) through 2026
    Characterization and quantification of market potential for In Vitro Diagnostics (IVD) analyzers by region, type, automation, application, therapeutic area and end user
    Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
    Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market trends, market size and market forecast
    Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
    Chapter 3 Ivd Analyzers Market: Background and Technology

DKT International Helps Maintain Global Access to Family Planning Despite Conflict and Inflation of Goods and Services

Retrieved on: 
Monday, April 25, 2022
Men, General Health, LGBTQ+, Social Media, Philanthropy, Family, Consumer, Marketing, Women, Communications, Medical Supplies, Other Philanthropy, Health, DKT, Condom, CEO, MVA, Lists of countries and territories, Domestic airport, Politics, Woman, Culture, Intrauterine device, WHO, Economics, DKT International, Birth, Sale, HIV/AIDS, Goal, Death, World, Solution, Social marketing, Reproductive health, Child, World War II, Health, HIV, Research, Birth control

Clinics close and doctors move on--despite such challenges, DKT International , one of the worlds largest providers of family planning, HIV/AIDS and safe abortion products and services, steps in to fill a growing unmet need as a critical provider of condoms and other contraception.

Key Points: 
  • Clinics close and doctors move on--despite such challenges, DKT International , one of the worlds largest providers of family planning, HIV/AIDS and safe abortion products and services, steps in to fill a growing unmet need as a critical provider of condoms and other contraception.
  • Often, in times of conflict, the right or ability to access family planning is one of the first things women lose, says Chris Purdy, CEO of DKT International.
  • Thats why we recommend women and girls can access abortion and family planning services when they need them.
  • And we will continue to ensure access to family planning triumphs even amidst differences in culture, economics, politics, gender, and religion.

Dalrada Health’s cerVIA™ Test Kit Enables Immediate Results with Second Cervical Cancer Screening Study Amid COVID-19 Restrictions

Retrieved on: 
Monday, April 25, 2022
Medical Devices, Health, Fitness & Nutrition, Medical Supplies, Oncology, COVID-19, Annual report, Colon, Acetic acid, Clinical trial, Climate change, Behavior, Woman, Form 10-K, WHO, Research, U.S. Securities and Exchange Commission, Cervical cancer, Hospital, Patient, VIA, Lung, Corporation, Trial of the century, Technology, Death, Company, OTCQB, Solution, SEC, Crowding, FDA, Cancer, Breast, Prostate, View, Medicine, Pharmaceutical industry, Birth control, Medical device, Renewable energy

Around the world, amid COVID-19 pandemic fears, cancer screening services were paused, and patients postponed preventative healthcare screenings.

Key Points: 
  • Around the world, amid COVID-19 pandemic fears, cancer screening services were paused, and patients postponed preventative healthcare screenings.
  • Dr. Payal Keswarpu, Dalrada Health's Chief Medical Officer, who led the cervical cancer screening study, shares, "Innovative tests and healthcare delivery can help restart screening services to reach the goal set by the WHO, to eliminate cervical cancer by 2030."
  • Cervical cancer contributes to a significant number of cancer cases every year, especially in developing countries with limited medical resources.
  • In the second preventive cervical cancer screening study conducted in India, one hundred women ages 31-65 were screened with Pap smear and VIA using the cerVIA kit.

Masimo SedLine® Brain Function Monitoring Reduced the Use of Anesthetic Agents and Opioids in a Study on Patients Undergoing Cardiac Surgery

Retrieved on: 
Monday, April 25, 2022
Technology, Surgery, Medical Devices, Medical Supplies, Clinical Trials, Cardiology, Hardware, Health, Pharmaceutical, Patient, Cardiopulmonary bypass, Adult, NASDAQ, Montreal Heart Institute Foundation, Kidney, MASI, CPB, Blood, Electroencephalography, Peege, ICU, OR, Mortality, Montreal Heart Institute, Journal, CVP, Psi, Anesthesia, Multimedia, VIS, Medical device

The researchers compiled a retrospective cohort of 300 adult patients who underwent cardiac surgery using CPB between 2013 and 2020 at the Montreal Heart Institute.

Key Points: 
  • The researchers compiled a retrospective cohort of 300 adult patients who underwent cardiac surgery using CPB between 2013 and 2020 at the Montreal Heart Institute.
  • The patients were divided into two groups, depending on whether anesthesia was guided by pEEG, which became a standard of care in 2017.
  • Patients in the pEEG group (n=150) had their brain function monitored, from the moment they entered the OR to arrival in the ICU, using Masimo SedLine.
  • Being in the pEEG group reduced the odds of being in a higher VIS category by 57% (OR=0.43; 95% confidence interval: 0.26-0.73; p=0.002).

Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross

Retrieved on: 
Monday, April 25, 2022
Medical Supplies, Medical Devices, Health, Infectious Diseases, Hospitals, Biotechnology, Red Cross, International Red Cross and Red Crescent Movement, Red, Cryoprecipitate, American Red Cross, Bleeding, Leadership, Hospital, Patient, LinkedIn, Corporation, Platelet, Factor, Plasma, Nasdaq, Transfusion medicine, World Red Cross and Red Crescent Day, Safety, Physician, FDA, CERS, Partnership, Transfusion transmitted infection, Blood product, Pharmaceutical industry, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.
  • Under the terms of this contract, Cerus will continue to supply the Red Cross the INTERCEPT Blood System used to produce pathogen reduced platelets, in support of the Red Cross goal to transition toward a full pathogen reduced platelet supply for its hospital customers across the U.S.
  • Cerus is proud of our long history of collaborating with the Red Cross, as they have played a critical role in the deployment of the INTERCEPT Blood System to safeguard the U.S. blood supply, stated William Obi Greenman, Cerus president and chief executive officer.
  • Thanks to their leadership and commitment to blood safety, the Red Cross is now the largest producer of INTERCEPT treated blood components in the world.

White Oak Commercial Finance Provides $7 Million Credit Facility to Converter and Distributor of Flexible Packaging Films

Retrieved on: 
Monday, April 25, 2022
Medical Supplies, Finance, Health, Consulting, Professional Services, Food, Beverage, Cosmetics, Retail, Growth, White, Solution, White oak, LLC, WOGA, Financial services

White Oak Commercial Finance, LLC (White Oak), an affiliate of White Oak Global Advisors, LLC, announced it provided a $7 million senior secured credit facility to a NY-based converter and distributor of flexible film packaging products for the medical, cosmetic, and food industries.

Key Points: 
  • White Oak Commercial Finance, LLC (White Oak), an affiliate of White Oak Global Advisors, LLC, announced it provided a $7 million senior secured credit facility to a NY-based converter and distributor of flexible film packaging products for the medical, cosmetic, and food industries.
  • The transaction was structured against the companys accounts receivable and inventory, and the proceeds will be used to support its continuing growth.
  • About White Oak Commercial Finance, LLC
    White Oak Commercial Finance, LLC (WOCF) is a global financial products and services company providing credit facilities to companies across the economy.
  • WOCF is an affiliate of White Oak Global Advisors, LLC and its institutional clients.

Alcon’s SMARTCataract Demonstrates Enhanced Efficiency and Time Savings for Cataract Surgeries

Retrieved on: 
Saturday, April 23, 2022
Software, Internet, Optical, Medical Supplies, Surgery, Health, Data Management, Technology, Cloud, INT, Society, Eye, ASCRS, Workflow, National Institute for Health and Care Excellence, Percussion section, Flaxman, Database, Master of Science, Approximation error, Cataract, American Society of Cataract and Refractive Surgery, Cataract surgery, Patient, Steroid, Severe cognitive impairment, Efficiency, Surgeon, Solution, Mark (given name), OR, Technology, Glaucoma, Lions Eye Institute, Meta-analysis, Ecosystem, Radiation, Mode-locking, Maintenance, NYSE, National Institute, Refractive surgery, Diabetes, ORA, Systematic review, Quality of life, Retina, Veterinary medicine, Medical device, Medical imaging, Computer data storage, Telescopic sight, Medicine, Alcon, IOL

SMARTCataract is the first application in Alcons comprehensive cloud-based platform uniquely designed for surgical ophthalmic practices.

Key Points: 
  • SMARTCataract is the first application in Alcons comprehensive cloud-based platform uniquely designed for surgical ophthalmic practices.
  • SMARTCataract links data systems and most diagnostic devices, including ARGOS Biometer with Image Guidance, with cataract surgical equipment, including LenSx Femtosecond Laser and LuxOR Revalia Ophthalmic Microscope.
  • Now, the SMARTCataract application also connects via the cloud to Alcons Optiwave Refractive Analysis (ORA) SYSTEM with VerifEye+, the only intraoperative aberrometer on the market.
  • Time differences in the diagnostic workup, pre-operative planning, intraoperative preparation and post-op were calculated and compared between the traditional workflow and SMARTCataract.

AdaptHealth Corp. Announces First Quarter 2022 Earnings Release Date and Conference Call

Retrieved on: 
Friday, April 22, 2022
Managed Care, Health, Medical Supplies, Medical Devices, NASDAQ, CPAP, HME, Obstructive sleep apnea, Stoma, Oxygen, PAP, Pulmonology, Interest, Diabetes, Company, Patient, Solution, Incontinence, Hospital, Medicare, Medicaid

AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2022 financial results before the opening of the financial markets on Tuesday, May 10, 2022.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2022 financial results before the opening of the financial markets on Tuesday, May 10, 2022.
  • ET to discuss the results and business activities with analysts and investors.
  • Interested parties may participate in the call by dialing:
    Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com under "Investor Relations."
  • AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services.